The HGF-MET Axis Coordinates Liver Cancer Metabolism and Autophagy for Chemotherapeutic Resistance

Overview

Journal Autophagy

Specialty Cell Biology

Date 2019 Feb 22

PMID 30786811

Citations 109

Authors

Xing Huang

Guangming Gan

Xiaoxiao Wang

Ting Xu

Wei Xie

Affiliations

Soon will be listed here.

Abstract

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles in liver carcinogenesis and metastasis, mainly dependent on the activity of receptor tyrosine kinase. However, for unknown reasons, all HGF-MET kinase activity-targeted drugs have failed or have been suspended in clinical trials thus far. Macroautophagy/autophagy is a protective 'self-eating' process for resisting metabolic stress by recycling obsolete components, whereas the impact of autophagy-mediated reprogrammed metabolism on therapeutic resistance is largely unclear, especially in liver cancer. In the present study, we first observed that HGF stimulus facilitated the Warburg effect and glutaminolysis to promote biogenesis in multiple liver cancer cells. We then identified the pyruvate dehydrogenase complex (PDHC) and GLS/GLS1 as crucial substrates of HGF-activated MET kinase; MET-mediated phosphorylation inhibits PDHC activity but activates GLS to promote cancer cell metabolism and biogenesis. We further found that the key residues of kinase activity in MET (Y1234/1235) also constitute a conserved LC3-interacting region motif (Y1234-Y1235-x-V1237). Therefore, on inhibiting HGF-mediated MET kinase activation, Y1234/1235-dephosphorylated MET induced autophagy to maintain biogenesis for cancer cell survival. Moreover, we verified that Y1234/1235-dephosphorylated MET correlated with autophagy in clinical liver cancer. Finally, a combination of MET inhibitor and autophagy suppressor significantly improved the therapeutic efficiency of liver cancer and in mice. Together, our findings reveal an HGF-MET axis-coordinated functional interaction between tyrosine kinase signaling and autophagy, and establish a MET-autophagy double-targeted strategy to overcome chemotherapeutic resistance in liver cancer. ALDO: aldolase, fructose-bisphosphate; CQ: chloroquine; DLAT/PDCE2: dihydrolipoamide S-acetyltransferase; EMT: epithelial-mesenchymal transition; ENO: enolase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLS/GLS1: glutaminase; GLUL/GS: glutamine-ammonia ligase; GPI/PGI: glucose-6-phosphate isomerase; HCC: hepatocellular carcinoma; HGF: hepatocyte growth factor; HK: hexokinase; LDH: lactate dehydrogenase; LIHC: liver hepatocellular carcinoma; LIR: LC3-interacting region; PDH: pyruvate dehydrogenase; PDHA1: pyruvate dehydrogenase E1 alpha 1 subunit; PDHX: pyruvate dehydrogenase complex component X; PFK: phosphofructokinase; PK: pyruvate kinase; RTK: receptor tyrosine kinase; TCGA: The Cancer Genome Atlas.

Citing Articles

Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications.

Park S, Hall M Exp Mol Med. 2025; .

PMID: 40025169 DOI: 10.1038/s12276-025-01415-2.

Single-cell sequencing reveals cell heterogeneity and aberrantly activated pathways associated with microvascular invasion in hepatocellular carcinoma.

Cui J, Zeng F, Tang M, Yin S Front Cell Dev Biol. 2025; 13:1449624.

PMID: 39944086 PMC: 11814199. DOI: 10.3389/fcell.2025.1449624.

B4GALNT1 Regulates Hepatocellular Carcinoma Cell Proliferation and Apoptosis via the PI3K-AKT-mTOR Pathway.

Bie L, Chen G, Lei X, Xiao F, Xu Z, Xiang Z J Clin Lab Anal. 2025; 39(4):e25155.

PMID: 39829207 PMC: 11848214. DOI: 10.1002/jcla.25155.

The protective role of baicalin regulation of autophagy in cancers.

Zhang Q, Guo S, Ge H, Wang H Cytotechnology. 2025; 77(1):33.

PMID: 39760060 PMC: 11699138. DOI: 10.1007/s10616-024-00689-0.

Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.

Zhang D, Zhang W, Liu H, Liu P, Li C, Liu Y Front Chem. 2024; 12:1501844.

PMID: 39720556 PMC: 11666382. DOI: 10.3389/fchem.2024.1501844.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V . Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer. 2013; 4(7-8):247-60. PMC: 3807646. DOI: 10.1177/1947601913501075. View

Bladt F, Friese-Hamim M, Ihling C, Wilm C, Blaukat A . The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel). 2014; 6(3):1736-52. PMC: 4190565. DOI: 10.3390/cancers6031736. View

Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G . EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013; 154(6):1269-84. PMC: 3917713. DOI: 10.1016/j.cell.2013.08.015. View

Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P . Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol. 2012; 14(2):177-85. DOI: 10.1038/ncb2422. View

Katayama R, Aoyama A, Yamori T, Qi J, Oh-Hara T, Song Y . Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013; 73(10):3087-96. PMC: 3759033. DOI: 10.1158/0008-5472.CAN-12-3256. View

Ogunwobi O, Puszyk W, Dong H, Liu C . Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 2013; 8(5):e63765. PMC: 3665785. DOI: 10.1371/journal.pone.0063765. View

Takeda S, Liu H, Sasagawa S, Dong Y, Trainor P, Cheng E . HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J Clin Invest. 2013; 123(7):3154-65. PMC: 3696564. DOI: 10.1172/JCI65566. View

Piguet A, Medova M, Keogh A, Gluck A, Aebersold D, Dufour J . Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes Cancer. 2015; 6(7-8):317-327. PMC: 4575919. DOI: 10.18632/genesandcancer.74. View

10.

Cheong H, Lu C, Lindsten T, Thompson C . Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012; 30(7):671-8. PMC: 3876738. DOI: 10.1038/nbt.2285. View

11.

Curthoys N, Watford M . Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995; 15:133-59. DOI: 10.1146/annurev.nu.15.070195.001025. View

12.

Galluzzi L, Pietrocola F, Bravo-San Pedro J, Amaravadi R, Baehrecke E, Cecconi F . Autophagy in malignant transformation and cancer progression. EMBO J. 2015; 34(7):856-80. PMC: 4388596. DOI: 10.15252/embj.201490784. View

13.

Junbo H, Li Q, Zaide W, Yunde H . Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo. 1999; 13(2):177-80. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

16.

Galluzzi L, Pietrocola F, Levine B, Kroemer G . Metabolic control of autophagy. Cell. 2014; 159(6):1263-76. PMC: 4500936. DOI: 10.1016/j.cell.2014.11.006. View

17.

Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M . Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice. Hepatology. 2016; 65(5):1581-1599. PMC: 5397318. DOI: 10.1002/hep.28975. View

18.

Madrigal-Matute J, Cuervo A . Regulation of Liver Metabolism by Autophagy. Gastroenterology. 2015; 150(2):328-39. PMC: 4728051. DOI: 10.1053/j.gastro.2015.09.042. View

19.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. DOI: 10.1038/nrc3205. View

20.

Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y . Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007; 178(1):93-105. PMC: 2064426. DOI: 10.1083/jcb.200703099. View